Ikrita Klair, MD
Pulmonary Disease · Las Cruces, NMNPI 1114239878
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $446 of the $558 with a category attached, or 80.0%. 10 manufacturers reported payments, led by Harmony Biosciences LLC at 24.8% of the total. Reporting peaked in 2019 at $266 and has fallen 53.5% since, to $124 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NM, where the typical reported total is $792.
Across 22 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$138
- Inspire Medical Systems, Inc.$98
- GSK$72
- Actelion Pharmaceuticals US, Inc.$70
- Mylan Specialty L.p.$66
- AstraZeneca$42
- plus $71 from 4 others
What the payments were for
- Food & beverage$44680%
- Education$11220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 2 | $138 |
| Inspire Medical Systems, Inc. | 1 | $98 |
| GSK | 5 | $72 |
| Actelion Pharmaceuticals US, Inc. | 3 | $70 |
| Mylan Specialty L.p. | 4 | $66 |
| AstraZeneca | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Baxter Healthcare | 1 | $17 |
| Boehringer Ingelheim | 1 | $14 |
| Grifols USA, LLC | 1 | $13 |
How this compares
$558 in reported general payments places this provider in the 40th percentile of 56 pulmonary disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 13 | $200,081 |
| SunosiSolriamfetol Hcl | 19 | $17,822 |
| BelsomraSuvorexant | 12 | $5,370 |
| Modafinil | 15 | $1,593 |
| Ropinirole Hcl | 18 | $788 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $492 |
| Eszopiclone | 22 | $486 |
| Trazodone Hcl | 40 | $371 |
| Clonazepam | 32 | $284 |
| Zolpidem Tartrate | 24 | $215 |
| Fluticasone Propionate | 15 | $212 |
| Hydroxyzine Hcl | 19 | $189 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Las Cruces
- Alan OrellanaLas Cruces$5K
- Alejandro ArzabalaLas Cruces$4K
- Lana Melendres GrovesAlbuquerque$1.1M
- Luke GabeSanta Fe$47K
- Michelle HarkinsAlbuquerque$24K
- Viral GandhiAlbuquerque$14K
- Gonzalo DiazAlamogordo$14K
- Arjan FloraAlbuquerque$10K
- Akshay SoodAlbuquerque$9K
- Sivakumar NagarajuAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.